Vol 13, No 6 (2024)
Editorial
Published online: 2024-12-13
Reality of Real-World Experience with Oral Semaglutide in Type 2 Diabetes
DOI: 10.5603/cd.103963
Clin Diabetol 2024;13(6):319-322.
Abstract
Not available
References
- Singh AK, Singh R, Misra A. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes Metab Syndr. 2022; 16(3): 102436.
- Ray S, Ray A, Goutam S, et al. Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study. Clin Diabetol. 2024; 13(6): 323–330.
- Bhattacharyya S, Saboo B, Mohit M, et al. Insights into the Early Use of Oral Semaglutide in Routine Indian Clinical Practice. International Journal of Diabetes and Technology. 2022; 1(4): 127–132.
- Kesavadev J, Ashik A, Yasmin S, et al. Effectiveness of Oral Semaglutide in Weight Loss and Glycemic Control among Type 2 Diabetes Population: A Real-world Longitudinal Study. International Journal of Diabetes and Technology. 2024; 2(3): 79–84.
- Singh AK, Singh R, Singh A, et al. Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence. Diabetes Metab Syndr. 2024; 18(5): 103024.
- Jain AB, Reichert SM, Amadid H, et al. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada). Diabetes Obes Metab. 2024; 26(5): 1799–1807.
- Kick A, M'Rabet-Bensalah K, Acquistapace F, et al. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study. Diabetes Ther. 2024; 15(3): 623–637.
- Saravanan P, Bell H, Braae UC, et al. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes. Adv Ther. 2024; 41(11): 4266–4281.
- van Houtum W, Schrömbges P, Amadid H, et al. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study. Diabetes Ther. 2024; 15(8): 1749–1768.
- Catrina SB, Amadid H, Braae UC, et al. PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice. Diabetes Ther. 2024; 15(9): 2079–2095.
- Yabe D, Hamamoto Y, Kawanami D, et al. PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. J Diabetes Investig. 2024; 15(11): 1566–1577.
- Rudofsky G, Amadid H, Braae UC, et al. Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies. Diabetes Ther. 2024 [Epub ahead of print].
- Topline: Oral Semaglutide Cuts Cardiovascular Events in T2D. https://www.medscape.com/viewarticle/topline-oral-semaglutide-cuts-cardiovascular-events-t2d-2024a1000jaa?form=fpf (30.11.2024).